TREM2 inhibited NF-κB and MAPK signaling activation mediated by toll-like receptor4 (TLR4) and tumor necrosis factor receptor-associated factor 6 (TRAF6) in MPTP-induced mice PD models, reducing MPTP-induced neuropathic changes [17]. Here, TLR4 is linked to Parkinson disease.